Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Forsteo® (Teriparatide): Patients with History of Breast Cancer
There is no specific information on the use of Forsteo (teriparatide) in patients with a past history of breast cancer.
Breast cancer is the most common type of cancer that metastasize to the bone. Take into consideration the risk of bone metastases and the length of time in remission before prescribing Forsteo.1
Relevant information from Summary of Product Characteristics
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).2
Forsteo is contraindicated in patients with prior external beam or implant radiation therapy to the skeleton.2
Information from Clinical Studies
Patients with a history of carcinoma in the previous five years or with a current suspicion were excluded from participating in clinical trials with teriparatide. However, patients with excised superficial lesions of the skin and those with a history of carcinoma in situ of the cervix or uterus were allowed to participate.3
There was no apparent increase in the incidence of cancers among all study participants treated with teriparatide compared with placebo during clinical trials.3
1. File E, Deal C. Clinical update on teriparatide. Curr Rheumatol Rep. 2009;11(3):169-176. http://link.springer.com/article/10.1007/s11926-009-0023-3
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 03 March 2020